leflunomide has been researched along with Vertigo in 1 studies
Leflunomide: An isoxazole derivative that inhibits dihydroorotate dehydrogenase, the fourth enzyme in the pyrimidine biosynthetic pathway. It is used an immunosuppressive agent in the treatment of RHEUMATOID ARTHRITIS and PSORIATIC ARTHRITIS.
leflunomide : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 5-methyl-1,2-oxazole-4-carboxylic acid with the anilino group of 4-(trifluoromethyl)aniline. The prodrug of teriflunomide.
Vertigo: An illusion of movement, either of the external world revolving around the individual or of the individual revolving in space. Vertigo may be associated with disorders of the inner ear (EAR, INNER); VESTIBULAR NERVE; BRAINSTEM; or CEREBRAL CORTEX. Lesions in the TEMPORAL LOBE and PARIETAL LOBE may be associated with FOCAL SEIZURES that may feature vertigo as an ictal manifestation. (From Adams et al., Principles of Neurology, 6th ed, pp300-1)
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Rahman, MU | 1 |
Poe, DS | 1 |
Choi, HK | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
A Pilot Trial of Rilonacept for Treatment of Autoimmune Neurosensory Hearing Loss[NCT02828033] | Early Phase 1 | 10 participants (Anticipated) | Interventional | 2017-02-01 | Recruiting | ||
Clinical Trial of Etanercept (TNF-α Blocker) for Treatment of Blast-Induced Tinnitus[NCT04066348] | Phase 2 | 310 participants (Anticipated) | Interventional | 2022-07-01 | Recruiting | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
1 other study available for leflunomide and Vertigo
Article | Year |
---|---|
Etanercept therapy for immune-mediated cochleovestibular disorders: preliminary results in a pilot study.
Topics: Adult; Aged; Antirheumatic Agents; Cochlear Diseases; Etanercept; Female; Follow-Up Studies; Hearing | 2001 |
Etanercept therapy for immune-mediated cochleovestibular disorders: preliminary results in a pilot study.
Topics: Adult; Aged; Antirheumatic Agents; Cochlear Diseases; Etanercept; Female; Follow-Up Studies; Hearing | 2001 |
Etanercept therapy for immune-mediated cochleovestibular disorders: preliminary results in a pilot study.
Topics: Adult; Aged; Antirheumatic Agents; Cochlear Diseases; Etanercept; Female; Follow-Up Studies; Hearing | 2001 |
Etanercept therapy for immune-mediated cochleovestibular disorders: preliminary results in a pilot study.
Topics: Adult; Aged; Antirheumatic Agents; Cochlear Diseases; Etanercept; Female; Follow-Up Studies; Hearing | 2001 |